BACKGROUND
Ceralasertib, an ATR inhibitor, is known to exacerbate replication stress induced by the PARP inhibitor (PARPi) olaparib, with the combination having the potential to overcome PARPi resistance in the clinic. This modular Phase 1 study evaluated the combination in advanced solid tumours, including breast canc...
J. Lopez, Seock-Ah Im, S. Postel-Vinay et al.· British Journal of Cancer· 0 citations
Abstract Background Hypoxia-inducible factor 2α (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and metastasis. Casdatifan is a potent, selective, orally bioavailable HIF-2α inhibitor that has demonstrat...
R. McKay, J. Merchan, A. Patnaik et al.· The Oncologist· 0 citations
PURPOSE
Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune feature...
Joseph J. Zhao, Choong-kun Lee, Allison S. Y. Chan et al.· Clinical Cancer Research· 0 citations
Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...
S. Rha, L. Wyrwicz, P. Yanez et al.· ESMO Open· 1 citation· ⚡1
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.